New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment

July 9, 2021 | Comments Off on New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment

Cancers (Basel) 2021 May 27 [Link] Giovanni Cugliari, Alessandra Allione, Alessia Russo, Chiara Catalano, Elisabetta Casalone, Simonetta Guarrera, Federica Grosso, Daniela Ferrante, Marika Sculco, Marta La Vecchia, Chiara Pirazzini, Roberta…

Surgical Management and Reconstruction of Diaphragm, Pericardium and Chest Wall in Mesothelioma Surgery: A Review

July 8, 2021 | Comments Off on Surgical Management and Reconstruction of Diaphragm, Pericardium and Chest Wall in Mesothelioma Surgery: A Review

Journal of Clinical Medicine 2021 May 26 [Link] Pietro Bertoglio, Elena Garelli, Jury Brandolini, Kenji Kawamukai, Filippo Antonacci, Sara Ricciardi, Alessandro Cipolli, Barbara Bonfanti, Sergio Nicola Forti Parri, Niccolò Daddi,…

Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma

July 7, 2021 | Comments Off on Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma

Cancers 2021 May 24 [Link] Francesca Napoli, Angela Listì, Vanessa Zambelli, Gianluca Witel, Paolo Bironzo, Mauro Papotti, Marco Volante, Giorgio Scagliotti, Luisella Righi Abstract Malignant pleural mesothelioma (MPM) is a…

NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

July 6, 2021 | Comments Off on NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

Journal of Translational Medicine 2021 May 31 [Link] Vilde Drageset Haakensen, Anna K Nowak, Espen Basmo Ellingsen, Saima Jamil Farooqi, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Tine Mcculloch, Oscar Grundberg, Susana…

Update on Diagnosing and Reporting Malignant Pleural Mesothelioma

July 5, 2021 | Comments Off on Update on Diagnosing and Reporting Malignant Pleural Mesothelioma

Acta Medica Academica 2021 April [Link] Ivana Savic, Jeffrey Myers Abstract In this review, we summarize current approaches to diagnosis of malignant pleural mesothelioma, focusing on the distinction from benign…

Old Borders and New Horizons in Multimodality Imaging of Malignant Pleural Mesothelioma

July 2, 2021 | Comments Off on Old Borders and New Horizons in Multimodality Imaging of Malignant Pleural Mesothelioma

The Thoracic and Cardiovascular Surgeon 2021 June 1 [Link] Katharina Martini, Thomas Frauenfelder Abstract Background: The purpose of this article is to describe the various imaging techniques involved in detection,…

Development of unenhanced CT-based imaging signature for BAP1 mutation status prediction in malignant pleural mesothelioma: Consideration of 2D and 3D segmentation

July 1, 2021 | Comments Off on Development of unenhanced CT-based imaging signature for BAP1 mutation status prediction in malignant pleural mesothelioma: Consideration of 2D and 3D segmentation

Lung Cancer 2021 July [Link] Xiao-Jie Xie, Si-Yun Liu, Jian-You Chen, Yi Zhao, Jie Jiang, Li Wu, Xing-Wen Zhang, Yi Wu, Hui Duan, Bing He, Heng Luo, Dan Han Abstract…

A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma

June 30, 2021 | Comments Off on A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma

Cell Death Discovery 2021 May 28 [Link] Surein Arulananda, Megan O’Brien, Marco Evangelista, Laura J Jenkins, Ashleigh R Poh, Marzena Walkiewicz, Trishe Leong, John M Mariadason, Jonathan Cebon, Srividya B…

The value of cytology in distinguishing malignant mesothelioma: An institutional experience of 210 cases reclassified according to the International System for Reporting Serous Fluid Cytopathology (ISRSFC)

June 29, 2021 | Comments Off on The value of cytology in distinguishing malignant mesothelioma: An institutional experience of 210 cases reclassified according to the International System for Reporting Serous Fluid Cytopathology (ISRSFC)

Cytopathology 2021 May 28 [Link] Patrizia Straccia, Daniele Magnini, Rocco Trisolini, Filippo Lococo, Marco Chiappetta, Alessandra Cancellieri Abstract Objective: Malignant mesothelioma (MM) is usually diagnosed by histological examination of tissue…

Identification of prognostic and bone metastasis​-related alternative splicing signatures in mesothelioma

June 28, 2021 | Comments Off on Identification of prognostic and bone metastasis​-related alternative splicing signatures in mesothelioma

Cancer Medicine 2021 May 26 [Link] Runzhi Huang, Zixuan Zheng, Sijia Liu, Penghui Yan, Dianwen Song, Huabin Yin, Peng Hu, Xiaolong Zhu, Zhengyan Chang, Yihan Liu, Juanwei Zhuang, Tong Meng,…

Categories